Faeth Therapeutics (FTH) Operating Expenses (2020 - 2026)
Faeth Therapeutics' (FTH) quarterly Operating Expenses came in at $170.6 million in Q1 2026, up 2245.71% YoY from $7.3 million in Q1 2025, and up 3342.14% on a QoQ basis from $5.0 million in Q4 2025.
Faeth Therapeutics (FTH) Operating Expenses (2020 - 2026) Analysis & Trends
Faeth Therapeutics (FTH) has 7 years of Operating Expenses data on file, last reported at $170.6 million in Q1 2026.
- Quarterly Operating Expenses rose 2245.71% year-over-year to $170.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $185.6 million (up 495.81% YoY) and the FY2025 annual result came in at $22.3 million, down 31.66% from the prior year.
- Operating Expenses advanced to $170.6 million in Q1 2026, from $5.0 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $170.6 million in Q1 2026 to a low of $4.9 million in Q3 2025.
- A 5-year average of $18.4 million and a median of $8.3 million in 2024 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2023 — Operating Expenses sank 44.5% — and 2026, when it jumped 2245.71%.
- Tracing FTH's Operating Expenses over 5 years: stood at $13.0 million in 2022, then tumbled by 37.6% to $8.1 million in 2023, then increased by 1.62% to $8.3 million in 2024, then sank by 40.09% to $5.0 million in 2025, then jumped by 3342.14% to $170.6 million in 2026.
- The last three Operating Expenses figures came in at $170.6 million (Q1 2026), $5.0 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Faeth Therapeutics | 180.89 Mn | 180.89 Mn | - | 18.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.39 Mn |
| Mar 31, 2026 | 170.63 Mn |
| Dec 31, 2025 | 4.96 Mn |
| Sep 30, 2025 | 4.85 Mn |
| Jun 30, 2025 | 5.21 Mn |
| Mar 31, 2025 | 7.27 Mn |
| Dec 31, 2024 | 8.27 Mn |
| Sep 30, 2024 | 7.82 Mn |
| Jun 30, 2024 | 7.79 Mn |
| Mar 31, 2024 | 8.73 Mn |
| Dec 31, 2023 | 8.14 Mn |
| Sep 30, 2023 | 7.74 Mn |
| Jun 30, 2023 | 10.18 Mn |
| Mar 31, 2023 | 11.01 Mn |
| Dec 31, 2022 | 13.05 Mn |
| Sep 30, 2022 | 13.94 Mn |
| Jun 30, 2022 | 10.71 Mn |
| Mar 31, 2022 | 12.49 Mn |
| Dec 31, 2021 | 9.41 Mn |
| Sep 30, 2021 | 10.32 Mn |